Bloom Health Partners Announces Closing of First Tranche of Private Placement

Bloom Health Partners Announces Closing of First Tranche of Private Placement

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces that it has closed an initial tranche of its non-brokered private placement offering (the "Offering") and has issued 5,150,000 units (the "Units") at $0.20 per Unit for gross proceeds of $1,030,000. The Units are comprised of (i) one (1) common share in the capital of the Company ("Common Shares"); and (ii) one-half (12) of a transferable common share purchase warrant (each whole warrant, a "Warrant" and collectively, the "Warrants"). Each Warrant entitles the holder thereof to acquire one (1) additional Common Share (each, a "Warrant Share") in the capital of the Company at a price of $0.30 per Warrant Share until July 6, 2023. The net proceeds of the Offering will be used by the Company for ongoing working capital and corporate development.

The initial tranche of the Offering was led by Ascenta Finance Corp., an exempt market dealer based in Vancouver, British Columbia. In connection with closing the initial tranche of the Offering, the Company paid $39,900, issued 3,000 Warrants, exercisable at a price of $0.20 per Warrant Share until July 6, 2023, and 196,500 compensation options (each, an "Option") to certain arms-length parties who assisted in introducing subscribers to the Offering. Each Option is exercisable to acquire a Unit under the same terms as the Offering until July 6, 2023. All securities issued in connection with the Offering are subject to a statutory hold period until November 7, 2022 in accordance with applicable securities laws.

The Offering included participation by the Chief Executive Officer of the Company in the amount of 50,000 Units. The purchase constitutes a related-party transaction within the meaning of Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions) ("MI 61-101"). The purchase is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of the Units issued to, and the consideration paid by, the Chief Executive Officer did not exceed twenty-five percent of the Company's market capitalization.

About Bloom Health Partners Inc.

Bloom Health Partners Inc. is a global platform for healthcare security, diagnostic testing and occupational health-tech. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Our stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

About Ascenta Finance Corp.

Ascenta Finance, headquartered in Vancouver, BC, is an Exempt Market Dealer registered in the provinces of BC, Alberta, Saskatchewan, Manitoba and Ontario. Ascenta connects qualified investors with quality companies that provide compelling investment opportunities with significant upside potential.

For more information on the Company, please email investors@bloomhealthpartners.com

To express an interest in participating in the Offering, please contact Marshall Farris at Ascenta Finance Corp. (marshall@ascentafinance.com).

On behalf of the board of directors,

Bloom Health Partners Inc.
Andrew Morton, Chief Executive Officer

Forward-Looking Statements

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/130200

News Provided by Newsfile via QuoteMedia

BLMH:CNX
The Conversation (0)
Bloom Health Partners Announces Leadership Transition

Bloom Health Partners Announces Leadership Transition

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of diagnostic and health technology services, announces a leadership transition.

Effective September 30, 2022, Andrew Morton has stepped down as CEO of the Company to pursue other opportunities. Rosemary Elliston, COO of the Company, has been appointed to the position of Interim CEO. Mr. Morton will continue to support the Company as a Director.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Announces New Location in Hawaii

Bloom Health Partners Announces New Location in Hawaii

New Bloom lab will support operations in the Honolulu area and surrounding region

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces the opening of a new location in in the Honolulu area.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners CEO to Speak at Health Benefits Nation Conference in Orlando

Bloom Health Partners CEO to Speak at Health Benefits Nation Conference in Orlando

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces its CEO, Andrew Morton, will speak on a panel at Health Benefits Nation Conference in Orlando, Florida on September 15th, 2022.

Mr. Morton will join co-panelists Eric Hargan, former U.S. Federal Deputy Secretary of the Department of Health and Human Services (DHHS), and Jeff Hogan, President of Upside Health Advisors. The panel titled "Incorporating Occupational Health into Value Based Health Strategies" will focus on workplace health and using data models to improve outcomes in occupational health in such areas as preventive care and mental health.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Reports Profitable Fiscal Q3 2022 with $8.4 Million in Revenue

Bloom Health Partners Reports Profitable Fiscal Q3 2022 with $8.4 Million in Revenue

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces unaudited Fiscal Q2 2022 revenues of CAD $8.4M for the three months ended June 30th, 2022, bringing year-to-date revenues to CAD $24.9M for the first three quarters of Fiscal 2022.

Highlights in Fiscal Q2 2022:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Announces New Location to Serve Chicago and Surrounding Area

Bloom Health Partners Announces New Location to Serve Chicago and Surrounding Area

New Bloom lab in the Chicago area will serve as a foothold in the midwestern United States

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D84) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces the opening of a new location in the Chicago area.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
RETRANSMISSION: Spearmint More Than Doubles the Acreage of the George Lake South Antimony Project in New Brunswick, Canada

RETRANSMISSION: Spearmint More Than Doubles the Acreage of the George Lake South Antimony Project in New Brunswick, Canada

Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the "Company" or "Spearmint") wishes to announce that it has more than doubled the acreage on the recently acquired George Lake South Antimony Project in New Brunswick, Canada. This project now consists of 4,722 contiguous acres prospective for antimony.

James Nelson, President of Spearmint stated, "In light of the recent ban of antimony by China to the USA, we made this strategic acquisition increasing the size of the George Lake South Antimony Project. Management feels that antimony will be one of the most sought after resources in 2025 and we plan to pursue this space with vigor and are currently evaluating additional projects. Management is formulating a plan on the George Lake South Antimony Project, and management also intends to update the market on Spearmint's crypto diversification plan in the near future as well. These are truly exciting times for Spearmint and Spearmint shareholders."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Elon Musk.

Tech 5: Musk Faces SEC Clash, Broadcom Surges, Google Makes Quantum Chip Breakthrough

Tech stocks surged this week as US and Canadian jobs data bolstered interest rate cut expectations.

Broadcom (NASDAQ:AVGO) became the newest member of the trillion-dollar club, crossing the market cap threshold in early trading on Friday (December 13) after a strong earnings forecast caught attention. Meanwhile, its peer NVIDIA (NASDAQ:NVDA) suffered losses as it prepares to face probes in both China and the US.

Meanwhile, Google (NASDAQ:GOOGL) announced a quantum computing milestone, and Tesla (NASDAQ:TSLA) CEO Elon Musk called out the US Securities and Exchange Commission (SEC) over multiple probes into his business dealings.

Keep reading...Show less
SEC website on phone screen.

SEC Reopens Investigation on Neuralink and Musk’s Twitter Deal

The US Securities and Exchange Commission (SEC) has reopened its investigation into Neuralink, Elon Musk’s brain-implant company, alongside a probe into Musk’s acquisition of Twitter, now rebranded as X.

A letter from Musk’s lawyer, Alex Spiro, disclosed the development on Thursday (December 12), raising questions about the ongoing legal disputes between Musk and the SEC, according to a Reuters report.

The letter, addressed to outgoing SEC Chair Gary Gensler, outlines the reopening of the Neuralink investigation and a settlement demand regarding the Twitter takeover, which happened in 2022.

Keep reading...Show less
Spearmint More Than Doubles the Acreage of the George Lake South Antimony Project in New Brunswick, Canada

Spearmint More Than Doubles the Acreage of the George Lake South Antimony Project in New Brunswick, Canada

Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the "Company" or "Spearmint") wishes to announce that it has more than doubled the acreage on the recently acquired George Lake South Antimony Project in New Brunswick, Canada. This project now consists of 4,722 contiguous acres prospective for antimony.

James Nelson, President of Spearmint, stated, "In light of the recent ban of antimony by China to the USA, we made this strategic acquisition increasing the size of the George Lake South Antimony Project. Management feels that antimony will be one of the most sought after resources in 2025 and we plan to pursue this space with vigor and are currently evaluating additional projects. Management is formulating a plan on the George Lake South Antimony Project, and management also intends to update the market on Spearmint's crypto diversification plan in the near future as well. These are truly exciting times for Spearmint and Spearmint shareholders."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Spearmint Announces Arrangements to Address Mailing Delays Resulting from Canada Post Strike

Spearmint Announces Arrangements to Address Mailing Delays Resulting from Canada Post Strike

Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the "Company" or "Spearmint") wishes to provide an update to shareholders on the impact of the strike by the Canadian Union of Postal Workers on the Company's ability to comply with its obligations to deliver to shareholders its financial statements and related disclosure and proxy-related materials in respect of the Company's annual general meeting of shareholders (the "Meeting") scheduled to be held at Cozen O'Connor LLP - 550 Burrard Street, Suite 2501, Vancouver, B.C., on Thursday, Dec. 19, 2024, at 10 a.m. PST.

James Nelson, President of Spearmint stated, "We want all of our shareholders to be aware of the current situation as there are many exciting events occurring for Spearmint in the short and medium term."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×